Dave Lennon, former president of Novartis Gene Therapies
September 21, 2021 03:29 PM EDTUpdated September 22, 06:31 AM
People
Bioregnum

So what hap­pened with No­var­tis Gene Ther­a­pies? Here's your an­swer

Over the last cou­ple of days it’s be­come clear that the gene ther­a­py di­vi­sion at No­var­tis has qui­et­ly un­der­gone a ma­jor re­or­ga­ni­za­tion. We learned on …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times